MedTrace Logo

Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

NCT00831467 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-03-20

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of a new vaccine in hormone refractory prostate cancer

Conditions

  • Hormonal Refractory Prostate Cancer

Interventions

BIOLOGICAL

CV9103

Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.

Sponsors & Collaborators

  • CureVac

    lead INDUSTRY

Principal Investigators

  • Kurt Miller, Professor · PMID: 19143027

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-12-31
Completion
2013-09-30

Countries

  • Germany
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00831467 on ClinicalTrials.gov